
Brian M Slomovitz MD
Gynecologic Oncology
Division Chief Gynecologic Oncology
Join to View Full Profile
1600 S Andrews AveFort Lauderdale, FL 33316
Phone+1 954-355-4345
Fax+1 954-527-4889
Dr. Slomovitz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Brian Slomovitz is an esteemed Obstetrics and Gynecology specialist with a subspecialty in Gynecologic Oncology, based in Fort Lauderdale, Florida. He completed his medical degree at Rutgers New Jersey Medical School in 1998, followed by a residency in Obstetrics and Gynecology at New York Presbyterian Hospital (Cornell Campus). He also undertook a fellowship in Gynecologic Oncology at the University of Texas M D Anderson Cancer Center. Since 2014, he has been the Division Director at the University of Miami Leonard M. Miller School of Medicine. He is proficient in various areas, including gynecologic oncology, clinical research, and minimally invasive and robotic gynecologic surgery. He has contributed to several key publications and been involved in numerous clinical trials. Dr. Slomovitz has received several accolades including Regional Top Doctor from Castle Connolly in 2014 and Fellow (FACOG) from the American Congress of Obstetricians and Gynecologists.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2002 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 1998 - 2002
Rutgers New Jersey Medical SchoolClass of 1998
Certifications & Licensure
FL State Medical License 2014 - 2028
NJ State Medical License 2008 - 2015
TX State Medical License 2002 - 2015
NY State Medical License 1999 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015-2017
Clinical Trials
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Publications & Presentations
PubMed
- Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industr...Robert L Coleman, Isabelle Ray-Coquard, Thomas J Herzog, Antonio González-Martín, Brian Slomovitz
International Journal of Gynecological Cancer. 2026-07-02 - Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.Gabriel Levin, Emily Eiley, Lucy Gilbert, Bradly J Monk, Robert L Coleman
International Journal of Gynecological Cancer. 2026-07-01 - Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy ou...Christian Marth, Domenica Lorusso, Mariusz Bidziński, Paolo Scollo, Mehmet Ali Vardar
International Journal of Gynecological Cancer. 2026-07-01
Press Mentions
Phase 3 Survival Data Show Combo Regimen Is a “Game Changer” For Ovarian CancerApril 13th, 2026
Possible Practice-Changing Trials on Tap for 2026 SGO Annual Meeting on Women’s CancerApril 3rd, 2026
Combo Regimen Produces Meaningful Response in Phase 2 Ovarian Cancer TrialFebruary 3rd, 2026
Committees
- Member, Uterine Corpus Committee, Gynecologic Oncology Group 2010 - Present
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









